350

THE CLINIC

SECTION 12

ISSUE 001

PROJECTIONinteraction1-3yconfidence / medium

Rare-Disease Variant Caseboards

Projection: rare-disease teams will work from a shared, living caseboard that joins regulatory variants, phenotypes, molecular evidence, and candidate experiments. Its value is not a single answer. It is a visible history of why hypotheses rose, what evidence is missing, and where clinicians, geneticists, and families still disagree.

Why this idea is here

What the evidence establishes.

AlphaGenome expands computational attention to non-coding effects; Bridge2AI is developing multimodal biomedical resources and responsible health-science networks.

Source ledger

Read the sources.

  1. S01
    Predicting Non-Coding Variant Effects with AlphaGenome

    peer-reviewed research highlight / published 2026-04-08 / retrieved 2026-07-09

  2. S02
    NIH Common Fund Bridge2AI Program Advances to Next Stage

    official program announcement / published 2026-01-30 / retrieved 2026-07-09

Back to all 500 ideas